Fujifilm To Sell Radiopharm Business; Avantor Investing in Hydration ServicesBy
The latest from CDMOs, CMOs, and suppliers featuring Fujifilm Toyama Chemical, Avantor, Thermo Fisher Scientific, SK pharmteco, BioDuro-Sundia, ten23 health, and others.
Chemicals/Chemical API Manufacturing
Fujifilm To Sell Radiopharmaceutical Business to PeptiDream for $277 M
Fujifilm Corporation has announced the transfer of the radiopharmaceutical business of its subsidiary, Fujifilm Toyama Chemical, to PeptiDream, a peptide-based drug-discovery company, for JPY 30.5 billion ($277 million) and potential contingent payments. The transfer date is scheduled for March 2022.
Fujifilm Toyama Chemical’s radiopharmaceutical business will be succeeded to the new radiopharmaceutical company, established by Fujifilm through an absorption-type company split, and all outstanding shares of the new radiopharmaceutical company will be transferred to PeptiDream.
Source: Fujifilm Corporation
Avantor investing in Hydration Services for Biologics
Avantor, a supplier of ultra-high-purity materials for the life sciences and advanced technology industries, has announced a multi-year investment in its global hydration capabilities.
The company recently completed an expansion of its facility in Gliwice, Poland and has begun a multi-stage expansion of its facility in Aurora, Ohio that will be completed by mid-2022.
The expansion will increase the company’s existing water-for-injection (WFI)-quality water buffer manufacturing capacity.
SK pharmteco Appoints New President for SK biotek Ireland
SK pharmteco, a Rancho Cordova, California-headquartered CDMO, has announced that Joyce Fitzharris, currently serving as General Manager of SK biotek Ireland has been promoted to President of SK biotek Ireland.
Ms. Fitzharris has worked within the active pharmaceutical ingredients (API) business for 30 years. She has held multiple technical, compliance, operational excellence, and leadership positions with increasing levels of responsibility with Bristol Myers Squibb and SK biotek Ireland.
Source: SK pharmteco
FairJourney Biologics Expands into New Portugal Facilities
FairJourney, a Porto, Portugal-based company that discovers and optimizes antibodies, has relocated into a larger research center in Porto.
FairJourney Biologics now occupies over 200,000 square feet, with the new premises containing 140 laboratories, meeting rooms and social areas, and green spaces.
Formulation Development/Drug Product Manufacturing
BioDuro-Sundia Acquires Drug-Product Mfg Facility
BioDuro-Sundia, a contract research, development and manufacturing organization (CRDMO) for active pharmaceutical ingredients (APIs) and drug products, has agreed to acquire a 40,000-ft2 commercial oral solid-dose manufacturing facility in Irvine, California.
BioDuro-Sundia expects to begin commercial service operations at the site on January 1, 2022. Capabilities of the new site include more than 1-billion-unit annual capacity in tableting and encapsulation as well as aqueous and organic solvent processing for fluid-bed and coating capabilities.
BioDuro-Sundia says it is making new equipment investments in support of the commercial operation, including commercial spray-drying capacity up to 100 kg/hr and hot-melt extrusion capacity up to 30 kg/hr. These capabilities provide a commercial extension to the company’s existing oral-solid development and manufacturing capabilities.
BioDuro-Sundia was formed in October 2020 from a partnership between BioDuro, a San Diego, California-headquartered CRDMO backed by Advent International, a Boston, Massachusetts-based private-equity firm, and Sundia, a Shanghai, China-based CRDMO.
ten23 health Launches as New CDMO
3i Group, a London-based investment group, has launched ten23 health, a new CDMO of injectable drugs based in Basel Switzerland. The company provides formulation development, drug-product development and manufacturing as well as testing services for sterile pharmaceutical products
ten23 health is headed by CEO, Hanns-Christia Mahler, who formerly led Lonza’s drug product dervices business. Prior to Lonza, he was Head of Pharmaceutical Development & Supplies at Roche, where he built its Biologics Product Development organization.
Thermo Fisher Granted $192.5 M from US Gov’t To Expand Pipette-Tip Mfg
Thermo Fisher Scientific has received a $192.5-million contract from the US Department of Defense (DoD) to expand domestic production of pipette tips.
With the DoD award, issued on behalf of and in coordination with the US Department of Health and Human Services (HHS), Thermo Fisher will co-invest with the US government in building a new manufacturing facility for pipette tips, which are used in disease research and for processing of diagnostic tests, including for COVID-19. In mid-2020, the company announced its own investments to increase pipette tip production capacity to support COVID-19 testing.
The new center of excellence in laboratory consumables manufacturing and operations will be in North Carolina with construction scheduled to fully completed by the third quarter of 2024, with pipette tip manufacturing starting as early as the third quarter of 2023.
Source: Thermo Fisher Scientific